Clinical Trials

84 enrolled

Lymphoma

NCT06137144 2026-05-19

PRIMAVERA

161 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT07167381 2026-05-19

xDRIVE for Florida-based Cancer Patients

Phase NA Recruiting

210 enrolled

Leukemia, Lymphoma, Neoplasms, Recurrence

NCT02332668 2026-05-18

MK-3475-051

370 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT04662255 2026-05-15

BRUIN-MCL-321

500 enrolled

Phase 1 Not yet recruiting

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07583771 2026-05-13

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

186 enrolled

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06678659 2026-05-08

DAHLIA

170 enrolled

Lymphoma, Neoplasms

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

40 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCORE™FL-2

Phase 3 Recruiting

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT07453446 2026-05-06

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Phase 1 Withdrawn

Lymphoma, Recurrence

NCT06084936 2026-05-04

GLOBRYTE

Phase 3 Recruiting

182 enrolled

Lymphoma

NCT06132503 2026-05-04

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

110 enrolled

LymphoidSarcoma

Lymphoma, Neoplasms, Recurrence, Sarcoma

NCT06624085 2026-05-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT07249905 2026-05-04

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

180 enrolled

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT04588922 2026-05-01

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06035497 2026-05-01

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

85 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT06441331 2026-05-01

KinLET

CNSEndocrineGastrointestinalLymphoidNETSarcoma

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT02732275 2026-04-28

DS-3201b in Participants With Lymphomas

DermatologicLymphoidOther hematologic neoplasm

100 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04384484 2026-04-28

LOTIS 5

440 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04666038 2026-04-24

BRUIN CLL-321

238 enrolled 17 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06801002 2026-04-24

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

25 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT02661542 2026-04-23

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Completed

106 enrolled 29 charts

Lymphoma

NCT05189093 2026-04-20

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Phase 1/2 Completed

48 enrolled

Phase 1 Not yet recruiting

Lymphoma

NCT07192471 2026-04-20

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

72 enrolled

DermatologicLymphoid

Immune System Diseases, Lymphoma, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05475925 2026-04-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

DermatologicLymphoidOther hematologic neoplasm

200 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

152 enrolled

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

70 enrolled

Blast Crisis, Leukemia, Lymphoma, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04329728 2026-04-15

OPAL

144 enrolled

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05131022 2026-04-14

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

572 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07221500 2026-04-14

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Phase 2 Recruiting

100 enrolled

Phase 1 Not yet recruiting

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07518329 2026-04-08

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

46 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT06522737 2026-04-06

TERZO

Phase 3 Recruiting

124 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

45 enrolled

Phase 3 Not yet recruiting

Lymphoma, Lymphoma, Non-Hodgkin

NCT07509151 2026-04-03

SOUNDTRACK-C1

420 enrolled

Leukemia, Lymphoma, Leukemia, B-Cell

NCT07284433 2026-04-02

QUADvance

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06915246 2026-03-27

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

Phase 2 Recruiting

49 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT07082803 2026-03-27

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

180 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

65 enrolled

Phase 1/2 Active not recruiting

Lymphoma

NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

253 enrolled

GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

NCT04830137 2026-03-20

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

248 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

54 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT03478462 2026-03-18

CLOVER-2

CNSGenitourinaryLymphoidSarcoma

30 enrolled

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05290597 2026-03-05

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

40 enrolled